Trevor Martin (Mammoth)
August 14, 2020 10:26 AM EDTUpdated 12:40 PM
Deals
R&D

Eye­ing in-vi­vo edit­ing, Mam­moth li­cens­es Jen­nifer Doud­na’s new CRISPR en­zyme

Jason Mast

Editor

Last month, Jen­nifer Doud­na re­vealed in Sci­ence a new, “hy­per-com­pact” CRISPR en­zyme that was half the size of tra­di­tion­al CRISPR en­zymes and could, she …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen

Paci­ra ab­sorbs GQ Bio for $32M; Lay­offs at BMS, Ei­sai and CRISPR Ther­a­peu­tics

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times